Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Azin Aghamajidi has a total of 151 co-authors. Here are the top co-authors by number of shared publications:

  • Xianxin Hua

    Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

    5 shared publications
  • Xuyao Zhang

    Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, China

    5 shared publications
  • Yuan Wu

    Department of Radiation Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China

    5 shared publications
  • Zhicheng Peng

    Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

    5 shared publications
  • Zijie Feng

    Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

    5 shared publications
  • Amarnath Rambhatla

    Vattikuti Urology Institute, Henry Ford Health

    3 shared publications

Latest Publications

  • Open Access

    Data from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts

    by Zijie Feng, Xuyao Zhang, Zhicheng Peng, Azin Aghamajidi, Yuan Wu, Xianxin Hua

    Gastrointestinal cancers (GIC), including gastric cancers and colorectal cancers, are among the leading causes of cancer-related deaths worldwide. Metastatic gastric cancers and colorectal cancers often develop resistance or fail to respond to current therapies. Adoptive T-cell immunotherapy, especially with T cells expressing chimeric antigen receptors (CAR) targeting CD19, has revolutionized leukemia treatment. However, the development of CAR T-cell therapy for GICs is still in progress. In this study, we used a sequentially tumor-selected antibody and antigen retrieval system to isolate a nanobody that directs CAR T cells to attack gastrointestinal tumor cells in preclinical mouse models. The nanobody VHHB30 specifically binds to the N-terminal (nonglycosylated) domain of carcinoembryonic antigens (CEA). The resulting VHHB30-CAR T cells (CEACAR T cells) exhibited cytotoxicity against both colorectal cancer and gastric cancer cell lines in vitro in a CEA-dependent manner. Moreover, third-generation CEACAR T cells showed enhanced antitumor activity compared with second-generation CEACAR T cells. Furthermore, in vivo studies demonstrated that the CEACAR T cells eradicated various colorectal and gastric tumor xenografts in preclinical mouse models, highlighting a promising approach for CAR T-cell therapy development in GICs through unbiased in vivo selection of potent VHH binders.


  • Open Access

    Supplemental Figure 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts

    by Zijie Feng, Xuyao Zhang, Zhicheng Peng, Azin Aghamajidi, Yuan Wu, Xianxin Hua

    Supplemental Figure 1. The nucleotide sequence (A) and amino acid residue sequence (B) of nanobody VHHB30.

  • Open Access

    Supplemental Table 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts

    by Zijie Feng, Xuyao Zhang, Zhicheng Peng, Azin Aghamajidi, Yuan Wu, Xianxin Hua

    Supplemental Table 1: Overview of Clinical Trials Investigating CEA-Targeted CAR T-cell Therapies in CEA-Positive Gastrointestinal and Solid Tumors

  • Open Access

    Supplemental Figure 2 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts

    by Zijie Feng, Xuyao Zhang, Zhicheng Peng, Azin Aghamajidi, Yuan Wu, Xianxin Hua

    Supplemental Figure 2. Proliferation and of VHHB30 3rd Generation CAR T Cells in Co-Culture with NB4/NB4CEA Tumor Cells. A. The CAR positivity of VHHB30 third-generation CAR T-cells. B. Total CD3 positive T cells increased 7days after co-culture with VHHHB30 third-generation CAR T-cells while not much in comparison to co-culture with NB4 wild type. C, D. The UTD and CAR T-cells proliferating in coculture with target NB4CEA tumor cells, while the cells decreased in other groups indicating the antigen-dependent stimulation effect of the immune synapse between CAR T-cells and its target. E. NB4CEA tumor cell numbers as a CD33 positive cell population decreased in co-culture with VHHHB30 third-generation CAR T-cells after day 2 indicating the cytotoxicity effect of VHHHB30 third-generation CAR T-cells.

  • Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts

    by Zijie Feng, Xuyao Zhang, Zhicheng Peng, Azin Aghamajidi, Yuan Wu, Xianxin Hua

    Gastrointestinal cancers (GIC), including gastric cancers and colorectal cancers, are among the leading causes of cancer-related deaths worldwide. Metastatic gastric cancers and colorectal cancers often develop resistance or fail to respond to current therapies. Adoptive T-cell immunotherapy, especially with T cells expressing chimeric antigen receptors (CAR) targeting CD19, has revolutionized leukemia treatment. However, the development of CAR T-cell therapy for GICs is still in progress. In this study, we used a sequentially tumor-selected antibody and antigen retrieval system to isolate a nanobody that directs CAR T cells to attack gastrointestinal tumor cells in preclinical mouse models. The nanobody VHHB30 specifically binds to the N-terminal (nonglycosylated) domain of carcinoembryonic antigens (CEA). The resulting VHHB30-CAR T cells (CEACAR T cells) exhibited cytotoxicity against both colorectal cancer and gastric cancer cell lines in vitro in a CEA-dependent manner. Moreover, third-generation CEACAR T cells showed enhanced antitumor activity compared with second-generation CEACAR T cells. Furthermore, in vivo studies demonstrated that the CEACAR T cells eradicated various colorectal and gastric tumor xenografts in preclinical mouse models, highlighting a promising approach for CAR T-cell therapy development in GICs through unbiased in vivo selection of potent VHH binders.


  • Open Access

    B lymphocytes in COVID-19: a tale of harmony and discordance

    by Amir Hossein Mansourabadi, Azin Aghamajidi, Maryam Dorfaki, Fatemeh Keshavarz, Zahra Shafeghat, Ali Moazzeni, Fahimeh Lavi Arab, Arezoo Rajabian, Mona Roozbehani, Reza Falak, et al.

    B lymphocytes play a vital role in the human defense against viral infections by producing specific antibodies. They are also critical for the prevention of infectious diseases by vaccination, and their activation influences the efficacy of the vaccination. Since the beginning of coronavirus disease 2019 (COVID-19), which became the main concern of the world health system, many efforts have been made to treat and prevent the disease. However, for the development of successful therapeutics and vaccines, it is necessary to understand the interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and the immune system. The innate immune system provides primary and nonspecific defense against the virus, but within several days after infection, a virus-specific immune response is provided first by antibody-producing B cells, which are converted after the resolution of disease to memory B cells, which provide long-term immunity. Although a failure in B cell activation or B cell dysfunction can cause a severe form of the disease and also lead to vaccination inefficiency, some individuals with B cell immunodeficiency have shown less production of the cytokine IL-6, resulting in a better disease outcome. In this review, we present the latest findings on the interaction between SARS-CoV-2 and B lymphocytes during COVID-19 infection.


  • Top Cited Papers
    Open Access

    Impact of Varicocele Repair on Semen Parameters in Infertile Men: A Systematic Review and Meta-Analysis

    by Ashok Agarwal, Rossella Cannarella, Ramadan Saleh, Florence Boitrelle, Murat Gül, Tuncay Toprak, Gianmaria Salvio, Mohamed Arafa, Giorgio I. Russo, Ahmed M. Harraz, et al.

    Agarwal A, et al. World J Mens Health. 2022 Oct;40:e70. https://doi.org/10.5534/wjmh.220142


  • Molecular Characteristics of Bladder Tumor: Increased Gene Expression of MAGE-A6 and MAGE-A11 with Decreased MicroRNA-34a and MicroRNA-125b

    by Azin Aghamajidi, Zahra Ousati Ashtiani, Monireh Mohsenzadegan, Nader Tajik, Mahmood Ghafoori Yazdi, Laleh Sharifi, Mohammad Reza Nowroozi

    Bladder cancer is recognized as one of the top ten most common cancers worldwide. Activation of oncogenes, inactivation of tumor suppressor genes, and dysregulation of androgen signaling pathways are three major pathophysiological causes in the development of bladder tumors. Discovering potential biomarkers is required for the management and immunotherapy of bladder cancer. Melanoma-associated antigen (MAGE)-A6 and MAGE-A11 are two cancer-testis antigens that are potential coregulators of androgen receptors. MicroRNAs, especially miR-34a and miR-125b are two important tumor suppressors that play a critical role in regulating different signaling pathways and inhibiting tumor development. Twenty-nine surgical tissue biopsies were collected from patients with no preoperative chemotherapy or radiotherapy (26 males and, 3 females, mean age±SD: 62.4±13.3 years). Seventeen adjacent uninvolved tissues with no abnormalities upon histological examination were considered normal controls (14 males and, 3 females, mean age±SD: 64.2±7.4 years) . Quantitative PCR was performed to evaluate the gene expression level of MAGE-A6, MAGE-A11, miR-34a, and miR-125b in bladder cancer biopsies. MAGE-A6 and MAGE-A11 expressions were significantly increased in bladder tumors compared with normal tissues. However, the expression levels of miR-34a and miR-125b were significantly downregulated in bladder tumor tissues. Interestingly, the expression level of all these genes was significantly associated with tumor grade, pathological stage (pT), and muscular invasion. MAGE-A6 and MAGE-A11 can be considered potential markers for the diagnosis and immunotherapy of bladder tumors. Furthermore, the modulation of miR-34a and miR-125b gene expression in association with increased MAGE-A6 and MAGE-A11 genes could open a new horizon in the improvement of bladder cancer.


  • Open Access

    Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy

    by Azin Aghamajidi, Pooya Farhangnia, Salar Pashangzadeh, Amirmasoud Rayati Damavandi, Reza Jafari

    Oncoviruses, known as cancer-causing viruses, are typically involved in cancer progression by inhibiting tumor suppressor pathways and uncontrolled cell division. Myeloid cells are the most frequent populations recruited to the tumor microenvironment (TME) and play a critical role in cancer development and metastasis of malignant tumors. Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), tumor-associated dendritic cells (TADCs), and tumor-associated neutrophils (TANs) exert different states from anti-tumorigenic to pro-tumorigenic phenotypes in TME. Although their role in the anti-tumorigenic state is well introduced, their opposing roles, pro-tumorigenic activities, such as anti-inflammatory cytokine and reactive oxygen species (ROS) production, should not be ignored since they result in inflammation, tumor progression, angiogenesis, and evasion. Since the blockade of these cells had promising results against cancer progression, their inhibition might be helpful in various cancer immunotherapies. This review highlights the promoting role of tumor-associated myeloid cells (TAMCs) in the pathophysiology of human virus tumorigenesis.


  • Open Access

    The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer

    by Azin Aghamajidi, Saman Maleki Vareki

    Gut microbiota can have opposing functions from pro-tumorigenic to anti-tumorigenic effects. Increasing preclinical and clinical evidence suggests that the intestinal microbiota affects cancer patients’ response to immune checkpoint inhibitors (ICIs) immunotherapy, such as anti-programmed cell death protein 1 (PD-1) and its ligand (PD-L1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Microbiota-induced inflammation possibly contributes to tumor growth and cancer development. Microbiota-derived metabolites can also be converted to carcinogenic agents related to genetic mutations and DNA damage in organs such as the colon. However, other attributes of microbiota, such as greater diversity and specific bacterial species and their metabolites, are linked to better clinical outcomes and potentially improved anti-tumor immunity. In addition, the intratumoral microbial composition strongly affects T-cell-mediated cytotoxicity and anti-tumor immune surveillance, adding more complexity to the cancer-microbiome-immune axis. Despite the emerging clinical evidence for the activity of the gut microbiota in immuno-oncology, the fundamental mechanisms of such activity are not well understood. This review provides an overview of underlying mechanisms by which the gut microbiota and its metabolites enhance or suppress anti-tumor immune responses. Understanding such mechanisms allows for better design of microbiome-specific treatment strategies to improve the clinical outcome in cancer patients undergoing systemic therapy.